Her2/Neu (QR003)

„[1] Menard S, Pupa SM, Campiglio M and Tagliabue E (2003): Biologic and therapeutic role of HER2 in cancer. Oncogene. 22: 6570-6578.
[2] Ellis CM, Dyson MJ, Stephenson TJ and Matlby EL (2005): HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques. J Clin Pathol. 58: 710-714.
[3] Muthuswamy SK, Gilman M and Brugge JS (1999): Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers. Mol Cell Biol. 19(10): 6845-6857.
[4] Klapper LN, Waterman H, Sela M and Yarden Y (2000): Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res. 60(13): 3384-3388.
[5] Ricardo SA, Milanezi F, Carvalho ST et al. (2007): HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas. J Clin Pathol. 60(9):1001-5.
[6] Hudziak RM, Schlessinger J and Ullrich A (1987): Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci U S A. 84(20):7159-63.
[7] Kokai Y, Cohen JA, Drebin JA and Greene MI (1987): Stage- and tissue-specific expression of the neu oncogene in rat development. Proc Natl Acad Sci U S A. 84(23):8498-501.“